Animal diseases and biosecurity

“Afrikkalaisesta sikaruttotartunnasta johtuvat liharaaka-aineen saatavuusongelmat painoivat Atria Viron liikevaihdon kehitystä.”

Annual report 2025A · The company itself

“Liikevoiton lasku johtui Atrian omilla sikatiloilla todetuista sikaruttotartunnoista, jotka aiheuttivat ylimääräisiä kustannuksia ja markkinahäiriöitä sekä liharaaka-aineen saatavuusongelmia.”

Annual report 2025A · The company itself

“Virossa on esiintynyt kesän aikana afrikkalaista sikaruttoa. Tällä hetkellä tilanne on rauhallinen, mutta tautiriski on edelleen olemassa.”

Annual report 2025A · The company itself

“Euroopan epävakaa sianlihamarkkina, eläintautiriskit ja alhainen kuluttajaluottamus Atrian kotimarkkinoilla ovat riskitekijöitä, jotka voivat vaikuttaa liikevoittoon lähitulevaisuudessa.”

Annual report 2025A · The company itself

“Atrialla on suojatoimenpiteitä käytössä omissa tuotantolaitoksissa ja sopimustuotantotiloilla.”

Annual report 2025A · The company itself

“Atria edellyttää eläinten hyvinvointipolitiikassa antibioottien vastuullista käyttöä tuotantoeläinten hoidossa. Antibioottien käytön vähentämisellä on pitkän aikavälin positiivinen vaikutus, koska se vähentää merkittävästi antibioottiresistenttien bakteerikantojen syntymistä ja leviämisriskiä ihmisiin.”

Annual report 2025A · The company itself

“Risk Risk description Risk mitigation Biological conditions BioMar is exposed to risk of changing biomass and feed consumption due to changes in biological conditions such as diseases, deformities, sea-lice, algae-blooms etc. Such risks are ever-present when farming animals in natural conditions.”

Annual report 2025A · The company itself

“BioMar sources approximately 347k tonnes of marine ingredients annually. Given the finite and fragile state of some fish species, our sourcing has a direct impact on marine resources. Fish stocks are naturally volatile and prone to supply fluctuations, which makes diversification of sourcing essential to reduce potential impacts.”

Annual report 2025A · The company itself

“Approximately one-third of BioMar’s raw material costs are related to marine ingredients. While promising alternatives are being developed and implemented, a significant need for omega-3 fatty acids of marine origin remains.”

Annual report 2025A · The company itself

“Marknaden för hematologitester för sällskapsdjur (hundar, katter, hästar och andra sällskapsdjur) förväntas nå 381,3 miljoner USD år 2029 med en förväntad årlig tillväxt på 8,4 % från en uppskattad summa på 258,8 miljoner USD år 2024.”

Annual report 2024A · The company itself

“Boule Diagnostics AB (publ) / Hematologitestning Hematologitester för veterinärmarknaden Veterinärfältet omfattar en bred skala av institutioner, från små till medelstora kliniker och stora sjukhus till djur i det vilda, djurparker och olika vårdmiljöer.”

Annual report 2024A · The company itself

“We depend on a limited international source of supply for certain products, such as large research models, including NHPs. Disruptions to their continued supply from time to time arise from colony health problems (including as a result of the spread of diseases), export or import laws/restrictions or embargoes, tariffs, inflation, international trade regulations, foreign government or economic instability, severe weather conditions, increased competition among suppliers for models, disruptions to the air travel system, activist campaigns, commercial disputes, supplier insolvency, geopolitical disputes, or other ordinary course or unanticipated events.”

Annual report 2025A · The company itself

“(Cambodia) Ltd (KF)., a leading supplier of non-human primates (NHPs) located in Cambodia. The purchase price of KF was $510.0 million, of which $335.0 million was paid up-front, with the remaining $175.0 million deferred until the completion of certain post-close conditions.”

Annual report 2025A · The company itself

“On November 30, 2023, we completed our acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of NHPs located in Mauritius, resulting in a 90% controlling interest. We had previously acquired a 49% equity interest in 2022 for $90.0 million plus additional contingent payments up to $5.0 million based on future performance.”

Annual report 2025A · The company itself

“Our business is dependent on frequent and consistent deliveries of ingredients that comply with our Food with Integrity specifications, such as dairy (for cheese, sour cream and queso), and beef, pork and chicken that meets our Responsibly Raised requirements. We may experience shortages, delays or interruptions in the supply of ingredients and other supplies to our restaurants due to higher or more lucrative demand from other sources; inclement weather or natural disasters; animal disease outbreaks (such as avian flu); social or labor unrest; shortages of agricultural workers (including due to changes in immigration laws); operational disruptions at our suppliers, distributors or transportation providers (including due to cyberattacks, malware or ransomware); financial distress or insolvency of suppliers or distributors, or the inability of suppliers or distributors to manage adverse business conditions; or other conditions beyond our control.”

Annual report 2025A · The company itself

“Shortages, delays, or interruptions in the supply of food items and other supplies to our restaurants may be caused by animal disease outbreaks affecting livestock and/or poultry; severe weather; natural disasters such as hurricanes, tornadoes, floods, droughts, wildfires, and earthquakes; macroeconomic conditions, such as tariffs and trade disputes, resulting in disruptions to the shipping and transportation industries; labor issues, such as increased costs or worker shortages or other operational disruptions at our suppliers, vendors, or other service providers; the inability of our vendors or service providers to manage adverse business conditions, obtain credit, or remain solvent; or other conditions beyond our control.”

Annual report 2026A · The company itself

“Grisepriserne var i første halvår på et fornuftigt niveau – hvorimod priserne faldt i løbet af andet halvår. De faldende priser i efteråret skyldes blandt andet udbrud af afrikansk svinepest (ASF) i Spanien.”

Annual report 2025A · The company itself

“Ledelsesberetning ET særdeles udfordrende år Gode udbytter og høj effektivitet tynges af mundog klovesyge og lave salgspriser.”

Annual report 2025A · The company itself

“Fra daglig drift til kriseberedskab I alt otte FirstFarms-farme i Slovakiet kom under restriktionszoner, hvor dyr og produkter ikke måtte flyttes eller sælges. Desuden blev salg af dyr ramt af eksportrestriktioner, som var implementeret for at forhindre sygdomsspredning.”

Annual report 2025A · The company itself

“Rengøring og desinfektion af staldene samt planlægning af genopretningen af besætningen og manglende salg af mælk har i alt påvirket resultatet for 2025 negativt med 35 mDKK.”

Annual report 2025A · The company itself

“Strategi Efter FirstFarms blev ramt af FMD, blev fokus rettet mod genopbygning af kvægbesætningen i Slovakiet. Omfanget af denne opgave er, uden sammenligning, det største projekt der hidtil er blevet gennemført i FirstFarms. Det har naturligt sat vores strategi 2028 på pause, idet fokus har været rettet med genopbygningen af mælkeproduktionen.”

Annual report 2025A · The company itself

“Den globala överanvändningen av antiobiotika har lett till utvecklingen av antibiotikaresistens (AMR), vilket årligen orsakar uppskattningsvis 1,1 miljoner dödsfall. Det finns ett tydligt behov av ny diagnostik och precisionsbehandlingar i rätt tid för att motverka den globala ökningen av AMR och effektivt bota infektioner.”

Annual report 2024A · The company itself

“HKFoods kirjasi alas Baltian liiketoimintojen myyntiin liittyneen ehdollisen kauppahintasaamisen HKFoods tiedotti 26.9.2025 kirjaavansa alas ehdollisen kauppahintasaamisen, joka liittyi 31.8.2023 toteutettuun Baltian liiketoimintojen myyntiin virolaiselle AS Maag Gruppille. AS Maag Gruppin suurimmassa sianlihan tuotantoyksikössä todettiin elokuun 2025 lopussa afrikkalaista sikaruttoa (ASF). Eläintautitapauksella arvioidaan olevan merkittävä ja pitkäkestoinen negatiivinen vaikutus AS Maag Gruppin tulokseen, joka on laskentaperusteena ehdolliselle kauppahinnalle.”

Annual report 2025A · The company itself

“Sianlihamarkkinan volatiliteettiä lisää EU:n suurimmassa tuottajamaassa Espanjassa joulukuussa 2025 todettu afrikkalainen sikarutto (ASF).”

Annual report 2025A · The company itself

“Liiketoiminnan jatkuvuus edellyttää maatalouden elinvoimaisuutta, lihantuotannon jatkuvuutta sekä eläintautien hallintaa. – Toimet ilmastonmuutokseen sopeutumiseksi vaativat taloudellisia kannustimia ja kansallista poliittista ohjausta. – Toimet ilmastonmuutokseen sopeutumiseksi huomioidaan yhtiön strategia- ja hankintatyössä. – Vastuullisuusohjelman mukainen sitoutuminen SBTi:n tavoitteisiin ja sen sisältämiin mitattaviin toimenpiteisiin – Arvoketjun alkutuotannon ilmasto-osaamisen kasvattaminen – Yhtiö tukee lihantuotannon toimintaedellytyksiä.”

Annual report 2025A · The company itself

“Tuotantoeläinten terveys, hyvinvointi ja hyvä kohtelu ovat konsernin kestävän toiminnan edellytyksiä, joita HKFoods on sitoutunut edistämään arvoketjun kaikissa vaiheissa. Hyvinvoinnista vastaavat eläinten kasvatuksen osalta sopimustuotantotilat ja kuljetuksen ja teurastustoiminnan osalta HKFoods, joka voi vaikuttaa eläinten hyvinvointiin ja olosuhteisiin tiloilla tuottajasopimusten kautta.”

Annual report 2025A · The company itself

“– Yhtiö on riippuvainen toimenpiteistä, joilla sopimustuottajat edistävät tuotantoeläinten hyvinvointia. – Eläinten hyvinvointi kiinnostaa laajasti yhtiön eri sidosryhmiä ympäristö- ja eettisistä syistä. – Vastuullisuusohjelman mukainen sitoutuminen eläinten hyvinvointiin – HKFoodsin eläinten hyvinvointiin liittyvä politiikka ja ohjeet, toimivaltaisten viranomaisten ohjeet ja määräykset sekä lopetusasetuksen mukainen toimintaohje yleisesti lainsäädännön noudattamisen lisäksi – Eläinlääkäreiden ja muiden asiantuntijoiden neuvontapalvelut sopimustuottajille – Sopimusehdot, kuuluminen eläinten hyvinvointiohjelmiin (kuten Naseva ja Sikava) – Ulkoiset ja sisäiset auditoinnit Raaka-aineet ja toimittajat potentiaalinen negatiivinen keskipitkä – Mikäli yhtiö ei noudattaisi eläinten hyvinvointivaatimuksia, voisi tämä aiheuttaa eläinten terveydelle haitallisia vaikutuksia. – Yhtiö on riippuvainen toimenpiteistä, joilla sopimustuottajat edistävät tuotantoeläinten hyvinvointia. – Eläinlääkäreiden ja muiden asiantuntijoiden neuvontapalvelut sopimustuottajille – Sopimusehdot, kuuluminen eläinten hyvinvointiohjelmiin (kuten Naseva ja Sikava) – Ulkoiset ja sisäiset auditoinnit Suhteet tavaran- ja palveluntoimittajiin Raaka-aineet ja toimittajat tosiasiallinen positiivinen lyhyt – Toimittajien edellytetään noudattavan liikesuhteessa toimittajien toimintaohjeita.”

Annual report 2025A · The company itself

“• Valintatilanteessa ja yhteistyön aikana toimittajia arvioidaan suhteessa eläinten hyvinvointi-, tuoteturvallisuus-, laatu-, ympäristö-, sosiaalisen vastuun-, työterveys-, turvallisuus-, tietoturva- ja jatkuvuudenhallinnan kriteereihin. • Riskienhallinnan ja jatkuvan parantamisen varmistamiseksi hankintoja tehdään hyväksytyiltä toimittajilta, joiden kriteerien täyttymistä seurataan.”

Annual report 2025A · The company itself

“Vastuullisen hankinnan periaatteet sisältävät yksityiskohtaisemmat vaatimukset liittyen eläinten hyvinvointiin, tuoteturvallisuuteen, laatuun, ympäristöön ja sosiaalisen vastuun hallintaan, työterveyteen, turvallisuuteen, tietosuojaan, tietoturvaan ja liiketoiminnan jatkuvuuden hallintaan.”

Annual report 2025A · The company itself

“Olennaiset aiheet, jotka toimintaperiaate kattaa Keskeinen sisältö Kattavuus Vastuu toteutuksesta Ylin hyväksymistaho Saatavuus Koulutus* Eettiset toimintaperiaatteet (Code of Conduct) (päivitetty 2024) E1, E2, E4, E5, S1, S2, S4, G1 Määrittelevät yleiset puitteet HKFoodsin asianmukaista toimintaa ja käyttäytymistä koskevalle ohjeistukselle liittyen mm. ihmisoikeuksiin, työntekijöiden oikeuksiin, työterveyteen ja turvallisuuteen, ympäristövaikutusten vähentämiseen, eläinten terveyteen ja hyvinvointiin, tuotteiden laatuun ja turvallisuuteen, eettisyyteen liiketoiminnassa sekä viestintään ja tietojen jakamiseen (tuottajat, toimittajat, alihankkijat ja liikekumppanit) Toimitus johtaja Hallitus Verkkosivut ja intranet – Sisältyy osaan sopimuksista – Verkkokoulutus osana perehdytystä – Osa eettiset toimintaperiaatteet -verkkokoulutusta, joka tulee suorittaa joka toinen vuosi Toimittajien toimintaohjeet (Supplier Code of Conduct) (päivitetty 2023) E1, E2, E4, E5, S2, S4, G1 Periaatteet, joiden mukaisesti yhtiö toimii maailmanlaajuisesti koko arvoketjussa ja joita toimittajien tulee noudattaa toimittaessaan tavaroita ja palveluja HKFoodsille.”

Annual report 2025A · The company itself

“Mm. eläintautien hallinta vähentää alttiutta häiriöille ja hintavaihteluille.”

Annual report 2025A · The company itself

“The Company is subject to risks associated with the outbreak of disease in pork and beef livestock, and poultry flocks, including African swine fever (ASF), Bovine Spongiform Encephalopathy (BSE), pneumo-virus, Porcine Circovirus 2 (PCV2), Porcine Reproduction & Respiratory Syndrome (PRRS), Foot-and-Mouth Disease (FMD), Porcine Epidemic Diarrhea Virus (PEDv), and Highly Pathogenic Avian Influenza (HPAI).”

Annual report 2025A · The company itself

“Furthermore, HPAI was detected within the Company’s turkey supply chain during fiscal 2024 and fiscal 2025. HPAI could continue to be detected in the future. Future impacts of HPAI could reduce the production volume in the Company’s turkey facilities.”

Annual report 2025A · The company itself

“Additionally, the outbreak of disease may hinder the Company’s ability to market and sell products both domestically and internationally.”

Annual report 2025A · The company itself

“Future sales of key animal health products could be adversely affected by a number of risk factors including certain risks that are specific to the animal health business. For example, the outbreak of disease carried by animals, such as Avian Influenza or African Swine Fever, could lead to their widespread death and precautionary destruction as well as the reduced consumption and demand for animals, which could adversely affect the Company’s results of operations.”

Annual report 2025A · The company itself

“The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products.”

Annual report 2025A · The company itself

“Animal Health The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as an extensive suite of digitally connected identification, traceability and monitoring products.”

Annual report 2025A · The company itself

“However, the ISA outbreak detected in two pens at the A-19 farming site in May required an early harvest of the entire site, reducing the total harvest volume and affecting achieved market prices negatively.”

Annual report 2024A · The company itself

“Proliferative Gill Disease (PGD) and Complex Gill Disease (CGD) are major challenges in Bakkafrost Scotland’s seawater production. These conditions are influenced by pathogens, environmental factors like plankton and suspended solids, and overall gill health.”

Annual report 2024A · The company itself

“However, the Faroese industry has encountered biological challenges, including fish health issues such as gill disease, stricter regulations, elevated levels of sea lice, and occasional production disruptions due to adverse weather conditions.”

Annual report 2024A · The company itself

“Bakkafrost reports the entity-specific metric of the percentage of soy that was sourced during the reporting year that was certified against Proterra or other certifications that include deforestation and/or conversion requirements. • Salmon escape incidents – Actual negative impact Bakkafrost can have a negative impact on the state of wild salmon stocks due to incidents in the company’s Farming segment where farmed salmon escape from their pens, caused by storms, predator interactions (e.g. seals), or damaged equipment. These escapes can result in farmed salmon being vehicles for the transfer of biological vectors to wild populations. Additionally, if farmed salmon interbreed with wild salmon, they might weaken the wild population because hybrids are less adapted to the natural environment and have lower reproductive success.”

Annual report 2024A · The company itself

“In 2024, Bakkafrost reported 3 incidents of fish escapes, 303 fish in total.”

Annual report 2024A · The company itself

“In Scotland, where wild salmon populations are present, we have implemented a strict zero-tolerance policy for escapes. This includes significant investments in enhanced containment systems, such as reinforced nets, mooring upgrades, and continuous monitoring technology.”

Annual report 2024A · The company itself

“In 2024, Bakkafrost allocated 190 mDKK toward cage infrastructure improvements, monitoring systems, and operational upgrades to ensure the security of farming operations.”

Annual report 2024A · The company itself

“By maintaining stringent controls and a commitment to continuous improvement, Bakkafrost reinforces its dedication to protecting biodiversity and supporting sustainable aquaculture practices • Sea lice management Bakkafrost has achieved record-low sea lice levels by implementing innovative strategies focused on minimizing ecological impact. Our efforts include the deployment of dualtreatment farming service vessels equipped with advanced freshwater systems to treat sea lice without relying on chemical interventions.”

Annual report 2024A · The company itself

“In 2024, Bakkafrost allocated 204 million DKK to the operation, investments and maintenance of these vessels and other related sea lice management activities.”

Annual report 2024A · The company itself

“Environmental and biological challenges have influenced our operational decisions and biological performance in 2024. Average weight, feed conversion ratio, growth, harvest volume, quality, and the proportion of production fish have been below our expectations.”

Annual report 2024A · The company itself

“SalMar strives to be at the forefront of adopting new technologies, equipment, and operational methods to reinforce our position as a leading sustainable salmon producer. Fish health and welfare remain our top priorities, reflected in our investment program, which focuses on continuous equipment and operational improvements.”

Annual report 2024A · The company itself

“A key concept for us is preventive technology, tailored to reduce lice pressure and avoid stressful lice treatments. This includes a combination of submerged, closed, or semi-closed technologies, supplemented by extensive use of laser-based lice control. By the end of 2024, approximately 20% of SalMar's sites were equipped with preventive technologies, with a particular focus on submerged equipment and lice lasers. We aim to double this number by the end of this year, ensuring that around 40% of our sites utilize such technologies.”

Annual report 2024A · The company itself

“SalMar has been a pioneer in this field, with our semi-offshore operational unit, Ocean Farm 1, now in its fourth production cycle. The results so far have been highly satisfactory, with strong growth, low fish mortality, and minimal sea lice—ensuring excellent fish welfare.”

Annual report 2024A · The company itself

“The segment has 2 semi-offshore units in operation, Arctic Offshore Farming and Ocean Farm 1. Early in 2024 harvest from both units were completed with strong biological performance.”

Annual report 2024A · The company itself

“SalMar has over the last years invested heavily in fish welfare equipment in order to reduce the sea lice pressure, and for 2025 investments in sea lice lasers and submerged net pens represent the largest investment.”

Annual report 2024A · The company itself

“Supply of and demand for our products can be adversely impacted by disease outbreaks impacting animals, animal products, and livestock, such as African swine fever (“ASF”), Bovine Spongiform Encephalopathy, Foot and Mouth Disease, Highly Pathogenic Avian Influenza (“HPAI”), and New World screwworm, which can have a significant impact on our financial results. In recent years, ASF has impacted hog herds in China, Asia, Europe, and the Caribbean, and if an outbreak of ASF were to occur in the United States, the Company’s supply of hogs and pork could be materially impacted.”

Annual report 2025A · The company itself

“HPAI has been detected in the United States in dairy cattle, wild birds, mammals, and farm workers directly exposed to infected dairy or poultry.”

Annual report 2025A · The company itself

“An outbreak of infectious disease carried by animals could negatively affect the sale and production of our products. Sales of our livestock products could be materially adversely affected by the outbreak of disease carried by animals, which could lead to the widespread death or precautionary destruction of animals as well as the reduced consumption and demand for animal protein. In addition, outbreaks of disease carried by animals may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products due to reduced herd or flock sizes.”

Annual report 2025A · The company itself

“In recent years, outbreaks of various diseases, including African Swine Fever, avian influenza and highly pathogenic avian influenza, foot-and-mouth disease, bovine spongiform encephalopathy (otherwise known as BSE or mad cow disease), New World screwworm, and porcine epidemic diarrhea virus (otherwise known as PEDv), have impacted the animal health business. The discovery of additional or more severe cases of any of these, or new diseases may result in additional restrictions on animal proteins, reduced herd sizes, or reduced demand for animal protein, which may have a material adverse effect on our operating results and financial condition.”

Annual report 2025A · The company itself

“Disease Outbreaks Sales of our livestock products have in the past, and may in the future be, adversely affected by the outbreak of disease carried by animals. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products.”

Annual report 2025A · The company itself

“We pursue the development of new vaccines for emerging infectious diseases, with an operating philosophy of “first to know and fast to market.” Examples of the successful execution of this strategy include the first SARS-CoV-2 (COVID-19) vaccine to help protect the health and well-being of more than 300 mammalian species living in zoos, aquariums, conservatories and other animal organizations around the world; the first equine vaccine for West Nile virus in the U.S. and EU; the first swine vaccine for pandemic H1N1 influenza virus in the U.S.; the first conditionally licensed vaccine against the pandemic H5N1 bird flu in the U.S. and EU, which we provided to the U.S.”

Annual report 2025A · The company itself

“Overview of our business We are a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.”

Annual report 2025A · The company itself

“Biological conditions Risk increased There is an ever-present risk of a disease outbreak across different fish and shrimp species, when farming animals in natural conditions, which changes biomass and feed consumption. The outbreaks are typically local or regional by nature.”

Annual report 2025A · The company itself

“The Company is subject to risks associated with economic, product quality, feed safety or other factors which may adversely affect the livestock and poultry businesses, including the outbreak of disease in livestock and poultry, for example African swine fever, which could adversely affect demand for the Company’s products used as ingredients in feed.”

Annual report 2025A · The company itself

“Table of Contents For instance, our use of animal-derived materials in certain products and manufacturing processes subjects us to regulatory, supply chain, quality, and reputational risks that could adversely affect our business. The sourcing, processing, importation, exportation, handling, storage, transportation and use of animal-derived materials are subject to complex and evolving laws, regulations and governmental oversight, including requirements administered by the USDA, APHIS, and the FDA, as well as customs authorities and comparable regulatory agencies in foreign jurisdictions.”

Annual report unknown yearA · The company itself

“HyperlinkHy perlinkHyper linkHyperlink Hyperlink Intermittent catheters People suffering from urinary retention are unable to empty their bladder, which can be due to a spinal cord injury, multiple sclerosis, congenital spina bifida or benign prostatic hyperplasia in men.”

Annual report 2025A · The company itself

“In Chronic Care, we launched Luja™, an intermittent catheter platform that addresses a major unmet need - reducing urinary tract infection risk. Supported by strong clinical evidence, Luja is the most significant Continence Care launch in a decade, and its rollout in key markets has received positive feedback from healthcare professionals and users.”

Annual report 2025A · The company itself

“Outbreak of foot and mouth disease (FMD) in Germany (January-April) impacting Continent-UK cold chain volumes”

Annual report 2025A · The company itself

“The latter was caused by a German outbreak of FMD (Foot & Mouth Disease).”

Annual report 2025A · The company itself

“We follow rigorous sourcing and manufacturing procedures intended to safeguard humans from potential risks associated with diseases such as bovine spongiform encephalopathy (“BSE”). We obtain bovine tissue used in our pericardial tissue valve products only from sources within the United States and Australia, where strong control measures and surveillance programs exist. In addition, bovine tissue used in our pericardial tissue valve products is from tissue types considered by global health and regulatory organizations to have shown no risk of infectibility.”

Annual report 2025A · The company itself

“Da uld anvendes i stort omfang i produkterne, prioriteres dyrevelfærd.”

Annual report 2025A · The company itself

“Den totala försäljningen av antimykotika för människor uppskattades år 2020 till cirka USD 16,7 miljarder.”

Annual report 2024A · The company itself

“Svampinfektioner blir alltmer ett globalt hälsoproblem, förknippat med hög sjuklighet och dödlighet samt förödande socioekonomiska konsekvenser. Omkring 90 procent av systemiska svampinfektionsrelaterade dödsfall orsakas av fem svamparter: Candida, Aspergillus, Kryptokocker, Pneumocystis och Mukormykos.”

Annual report 2024A · The company itself

“BLS’s preclinical services rely on healthy research animal populations. The presence of infectious or other diseases can compromise research quality, result in inventory loss, and pose risks to human or external animal populations.”

Annual report 2025A · The company itself

“As we prepare for regulatory studies and finalize our product for the human market, we are also targeting a launch in the veterinary market, where regulations are less stringent. This approach will allow us to gain valuable product experience, which will inform and strengthen our strategy for entering the human market.”

Annual report 2024A · The company itself

“Mowi expects to grow volumes from 73k GWT in 2024 to 77k GWT in 2025 and plans to increase volumes in the coming years in line with the traffic light system in Chile which aims at controlling the industry's sanitary situation.”

Annual report 2024A · The company itself

“Since 2020, the winter sore vaccine has become less efficacious. This, combined with an unusually cold winter and the largest prevalence of string jellyfish for 20 years, negatively impacted superior share and prices.”

Annual report 2024A · The company itself

“A new winter sore vaccine, helped by operational improvements, less string jellyfish and higher temperatures, have led to significantly improved biology in the 2024/2025 winter season.”

Annual report 2024A · The company itself

“Incident-based mortality costs totalled EUR 49.0 million in 2024, stable from EUR 48.9 million in 2023, mainly caused by gill issues and knock-on effects from lice treatments, in addition to winter sore issues.”

Annual report 2024A · The company itself

“Harvest volumes were 94 551 tonnes gutted weight, down from 99 124 tonnes in 2023 driven by enforced culling of small PD-positive fish at two sites towards the end of 2023.”

Annual report 2024A · The company itself

“The earnings effect of approx. EUR 29 million of upgrading downgraded salmon in Norway is included in the Markets segment and was higher than normal in 2024 due to the challenging winter sore situation.”

Annual report 2024A · The company itself

“Our results showed that CCS can keep sea lice levels below treatment thresholds and that recovery of valuable resources from the discharge is possible.”

Annual report 2024A · The company itself

“A significant step was made in sustainability through initiatives aimed at increasing fish health and welfare, carbon footprint reduction in our own operations, sourcing sustainable feed raw materials and increasing the inclusion of emerging feed raw materials, and increasing the due diligence of our supply chain.”

Annual report 2024A · The company itself

“Despite responsible use and residue control aligned with regulatory compliance, there is a reputational risk for Mowi when using antimicrobials. This is linked with the concern for antimicrobial resistance.”

Annual report 2024A · The company itself

“We monitor human-wildlife interactions, apply operational best practices and have preventive measures and equipment in place to avoid and minimise negative impact on local wildlife. All bird and mammal mortalities are registered with a special emphasis on red listed species.”

Annual report 2024A · The company itself

“Escapes Escaped farm-raised salmon may have a negative impact on the environment, due to ecological interactions and interbreeding with wild populations, and therefore we have a zero-fish escape target, every year, including 2024 and 2025.”

Annual report 2024A · The company itself

“Our Breeding and Genetics division continued to focus on genomic selection for lice resistance in the Mowi strain.”

Annual report 2024A · The company itself

“Vi tar steget in i två helt nya produkt kategorier, bilbarnstolar och hundtransport.”

Annual report 2023A · The company itself

“Public concern over avian flu may cause fear about the consumption of chicken, eggs and other poultry products derived from poultry, which could adversely affect us given that poultry is widely offered at our Concepts’ restaurants. Avian flu outbreaks could also adversely affect the price and availability of poultry, which could negatively impact our business.”

Annual report 2025A · The company itself

“Failure to do so will hinder new research and development opportunities, stifling innovation and reducing the availability of new treatments Animal welfare Own operations and value chain When Zealand Pharma or any of our business partners perform animal studies, it directly impacts the labo-ratory animals. Through our work and engagement with value chain partners, we do not only have a responsibility for ensuring ethical treatment of animals, but we also have an opportunity to enforce improved treatment of labora-tory animals and higher, more ethical welfare standards across our value chain Patient safety must never be compro-mised, and animal studies are crucial for ensuring the safety and efficacy of new treatments before they are used in humans Both Zealand Pharma and some of our partners conduct animal studies.”

Annual report 2025A · The company itself